Vanflyta
What Vanflyta is used for
Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Vanflyta
- Active substance
- quizartinib
- Disease area
- Leukemia, Myeloid
- Medicine group
- Antineoplastic agents;Protein kinase inhibitors
- ATC code
- L01EX11
- Marketing authorisation holder
- Daiichi Sankyo Europe GmbH
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Vanflyta
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vanflyta used for?
Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.
What is the active substance in Vanflyta?
Vanflyta contains quizartinib.
Who makes Vanflyta?
The EU marketing authorisation holder is Daiichi Sankyo Europe GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU